Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study.

Edouard J Louis, Hervé E Watier, Stefan Schreiber, Jochen Hampe, François Taillard, Allan Olson, Nicole Thorne, Hongyan Zhang, Jean-Frédéric Colombel
Year of publication:
Journal title abbreviated:
Pharmacogenet. Genomics
Journal title long:
Pharmacogenetics and genomics
Impact factor:
Recently, it has been shown that FCGR3A-158 gene polymorphism is associated with biological and possibly clinical response to infliximab in Crohn''s disease. We further assessed this association in a subset of 344 patients from the large and well-defined cohort of 573 patients with Crohn''s disease from the ACCENT I study. No association could be observed between FCGR3A-158 gene polymorphism and the clinical response to infliximab, which was primarily defined as a decrease of >or=70 points in the Crohn''s disease activity index or clinical remission (Crohn''s disease activity index <150). We did, however, confirm a trend towards a greater decrease in C-reactive protein after infliximab in V/V homozygotes as compared with V/F heterozygotes and F/F homozygotes (-79.4, -76.5, and -64.3%, respectively, at week 6; P=0.085; one-tailed P=0.043). This finding has no immediate clinical impact but may enhance the understanding of the complex mechanisms of action of anti-tumor necrosis factor agents in Crohn''s disease.